BIO-Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Ecosystem innovation at BIO‑Europe 2026

Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website

84 organizations at BIO-Europe 2026 present work in ecosystem innovation: 33 drug developers, 21 academic, government and non-profit bodies, 16 service providers and 14 investors. Between them they bring 131 presentations to the program. Most represented: Merck KGaA (11 on the program), Bayer (6 on the program), Boehringer Ingelheim (5 on the program). As of Nov 10, 2026.

All 473 organizations at BIO-Europe 2026 →

Format
Top represented
Showing 1–9 of 84 organizations
OrganizationBIO-Europe 2026 Attendance
Merck KGaA
Darmstadt, Germany
◆Platinum Sponsor
Large pharmaPlatinum sponsor
Science and technology company active in healthcare, life science and electronics; operates as EMD Serono and MilliporeSigma in North America.
Talk
Mon Nov 9
09:00–10:00
Building Your BD Career: What Really Moves the Needle
What it takes to build a career in drug licensing and partnership deals, from scientific and financial skills to credibility and contacts.
with BD&L Peers Community, Thuja Capital, Tubulis +1 more
Talk
Mon Nov 9
15:00–16:15
Merck's EMEA Advance Biotech Grant Program
Five young biotech companies pitch their science to Merck, competing for a grant that helps them bring a product to market.
with Stemmatters, M Ventures, ConvEyXO +4 more
Panel
Mon Nov 9
13:00–13:45
Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem
How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery.
with MichBio, XGEN Venture, Boehringer Ingelheim
Panel
Tue Nov 10
14:00–14:45
Immunology under the microscope: New frontiers
What is new in drugs for autoimmune and inflammatory diseases: emerging targets, recent trial results, and where companies are investing and partnering.
with MRM Health, Hansa Biopharma, Claris Ventures
Talk
Tue Nov 10
09:15–09:30
Pharma Presentation: Merck
Merck's three businesses: medicines for diseases such as multiple sclerosis and cancer, tools for scientists, and technology for electronics.
Panel
Tue Nov 10
16:00–16:45
Unlocking Clinical Trial Systems
How EU clinical trial rules and a planned EU biotech law affect trial approval times, and whether Europe can speed up safely.
with R Kupiec Consulting, Parexel, AstraZeneca
Panel
Wed Nov 11
09:00–09:45
From NAMs (New Approach Methodologies) Innovation to Regulatory acceptance: Accelerating human-relevant modelling
How lab models built on human biology, from organs-on-chips to AI computer models, can speed drug development and win regulators' acceptance.
with FRESCI, TissUse, European Commission +2 more
Bayer
Leverkusen, Germany
◆Platinum Sponsor
Large pharmaPlatinum sponsor
Life sciences company with pharmaceuticals, consumer health and crop science divisions.
Talk
Tue Nov 10
09:00–09:30
An Outlook into the Year 2050: Navigating the Future of Efficiency and Innovation
How AI, global expansion and patient community outreach may reshape the way clinical trials are run, and what to change now to prepare.
Panel
Tue Nov 10
15:00–15:25
Inside the Incubator: What It Really Takes to Build a Biotech Company Today
What incubators backed by big drug companies look for in young biotechs, and how they help founders with money, advice and partners.
with Phinomics
Panel
Tue Nov 10
16:30–16:55
The Role of Innovation in Biopharma Growth
How new ideas and technologies drive growth for drug companies, and how to keep innovating while scaling up, with real examples.
Panel
Wed Nov 11
10:00–10:45
AI Regulations: Driving Innovation While Navigating Compliance
What rules cover AI in drug development, where European and US regulators agree, and how rules could help rather than hinder innovation.
with European Medicines Agency
Panel
Wed Nov 11
11:00–12:00
Collaborative Innovation in CDMO Partnerships
How drug companies and contract manufacturers develop new therapies together, with examples of what makes these partnerships work and where they struggle.
with Eleva, Evotec
Boehringer Ingelheim
Ingelheim am Rhein, Germany
◆Platinum Sponsor
Large pharmaPlatinum sponsor
Family-owned pharmaceutical company developing human and animal health medicines.
Panel
Mon Nov 9
13:00–13:45
Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem
How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery.
with MichBio, XGEN Venture, Merck KGaA
Talk
Tue Nov 10
13:00–14:00
Biologics Manufacturing Excellence
How makers of biologics, drugs made in living cells, can expand capacity, clear production bottlenecks and use new technology to work more efficiently.
with Immatics, ValiRx, Pfizer +1 more
Talk
Tue Nov 10
09:30–09:45
Pharma Presentation: Boehringer Ingelheim
Boehringer Ingelheim, independent since 1885, and its research on human and animal medicines for diseases that lack good treatments.
Panel
Wed Nov 11
10:00–10:45
Envisioning the future of ophthalmology
What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise.
with Micro CRISPR, AAVantgarde Bio, Inveready +1 more
Panel
Wed Nov 11
10:00–10:45
Most Favoured Nations: A Game-Changer for Biotech Dealmaker?
How the US 'most favoured nation' policy, which ties US drug prices to prices paid abroad, is changing drug deals and European launch plans.
with EUCOPE, Bristol Myers Squibb
Informa
London, United Kingdom
Consulting, legal & services
Events, publishing and data group that runs BIO-Europe and publishes BioXconomy.
Keynote
Mon Nov 9
10:15–10:30
Opening Remarks
The Big Picture Plenary Series · with Ministry of Economic Affairs, Industry, Climate Action and Energy of North Rhine-Westphalia, Biotechnology Innovation Organization (BIO)
Talk
Mon Nov 9
09:30–10:00
partneringONE essentials workshop
Newcomers learn what to expect from partnering meetings, including timing and etiquette, and how to get the most from the partneringONE system.
Panel
Tue Nov 10
09:00–09:45
Networks or neurons: What’s next in CNS dealmaking?
What is driving recent deals between biotechs and larger drug companies for brain and nervous system drugs, which remain hard to develop.
with Servier, Biovance Capital, Otsuka +2 more
Talk
Tue Nov 10
11:30–12:00
partneringONE power up workshop
Experienced delegates learn advanced partneringONE features and team habits that save time and raise how often their meeting requests are accepted.
Panel
Wed Nov 11
13:00–13:45
BIO-Europe Media Round-Up: The Stories Shaping Biopharma Right Now
Journalists pick out the biggest biopharma news stories and deal trends of the moment and explain what they mean for dealmakers.
with BioWorld
Panel
Wed Nov 11
09:00–09:45
How is the APAC region reshaping global biopharma?
How China, Japan, South Korea and other Asia-Pacific countries are moving from making drugs to inventing them, and how Western firms can partner.
with MSD, Sinovoy Health Group, WinHealth Pharma +1 more
Johnson & Johnson
New Brunswick, NJ
◆Platinum Sponsor · Johnson & Johnson Innovation
Large pharmaPlatinum sponsor
Healthcare company developing innovative medicines and medical technologies; its Innovation unit partners with external researchers and start-ups.
Panel
Mon Nov 9
16:15–17:00
Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work?
What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies.
with 59 North Communications, Gateway Factory, CSL Behring +1 more
Panel
Tue Nov 10
10:00–10:25
Regulatory Updates for Orphan and Pediatric Medicines
How updated EU drug laws change the rewards for rare-disease and children's medicines, such as longer protection from competing copies.
Panel
Wed Nov 11
10:00–10:45
Envisioning the future of ophthalmology
What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise.
with Micro CRISPR, Boehringer Ingelheim, AAVantgarde Bio +1 more
Panel
Wed Nov 11
12:00–12:45
What's Next for Biomanufacturing Strategies?
Where the manufacturing of biological medicines is heading, from sturdier supply chains and industry mergers to AI and new ways to scale up.
with Resolution Therapeutics, Valneva, IDT Biologika
European Commission
Brussels, Belgium
Gov, delegations & associations
Executive body of the European Union, proposing legislation and running EU programmes, including health, medicines and research policy.
Panel
Tue Nov 10
09:00–09:45
Accelerating Innovation and Market Exclusivity Through Regulatory Incentives
How updated EU drug laws and the Biotech Act change how long new medicines are shielded from competing copies, compared with rules elsewhere.
with Sanofi, Swedish Medical Products Agency, Novartis
Panel
Tue Nov 10
14:30–14:55
Investing in Women’s Health: How Can Europe Scale Innovation?
How Europe can grow investment in women's health, previewing a European Investment Bank study of the field's research, unmet needs and funding options.
with European Investment Bank
Panel
Wed Nov 11
09:00–09:45
From NAMs (New Approach Methodologies) Innovation to Regulatory acceptance: Accelerating human-relevant modelling
How lab models built on human biology, from organs-on-chips to AI computer models, can speed drug development and win regulators' acceptance.
with FRESCI, Merck KGaA, TissUse +2 more
CSL Behring
King of Prussia, PA
◆Platinum Sponsor
Large pharmaPlatinum sponsor
CSL's biotherapeutics business, making plasma-derived and recombinant therapies for rare and serious diseases.
Panel
Mon Nov 9
16:15–17:00
Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work?
What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies.
with 59 North Communications, Gateway Factory, Sound Bioventures +1 more
Panel
Mon Nov 9
13:00–14:00
Navigating partnering and business development in a shifting global landscape
How funding conditions, treatment trends and geopolitics are shaping partnerships and acquisitions between drug and biotech companies, with real deal examples.
with Syneos Health, Biogen, Genmab +2 more
Panel
Tue Nov 10
14:00–14:45
Harnessing Regulatory Sandboxes to Drive Innovation in Novel Therapeutics & Technologies
How regulatory sandboxes, where regulators let new products be tested under adjusted rules, could support new therapies and health technologies in Europe.
with HTW Berlin, Innovative Health Initiative, European Medicines Agency
EUCOPE
Brussels, Belgium
Gov, delegations & associations
Trade association representing small and mid-sized innovative pharmaceutical and biotech companies in Europe.
Panel
Tue Nov 10
10:30–10:55
Addressing Unmet Medical Needs in Europe’s Evolving Pharmaceutical Landscape
How regulators judge which diseases lack good treatments, which faster approval routes apply, and whether recent EU drug law changes have helped.
with PTC Therapeutics
Panel
Wed Nov 11
12:00–12:45
HTA Regulation: Early Insights and Reimbursement Implications
Early lessons from the EU's new joint reviews of how much new drugs help patients, and whether they ease or hinder patient access.
with Lundbeck
Panel
Wed Nov 11
10:00–10:45
Most Favoured Nations: A Game-Changer for Biotech Dealmaker?
How the US 'most favoured nation' policy, which ties US drug prices to prices paid abroad, is changing drug deals and European launch plans.
with Bristol Myers Squibb, Boehringer Ingelheim
Miltenyi Biomedicine
Bergisch Gladbach, Germany
Biotech
Clinical-stage company of the Miltenyi Group developing CAR-T and other cell therapies for cancer and autoimmune disease.
Panel
Tue Nov 10
10:00–10:45
Accelerating Access to Innovative Therapies for European Patients Through Integrated Decision-Making
How approval, benefit reviews and pricing decisions could run side by side instead of one after another, so European patients get new medicines sooner.
with IGES Institut, Krystal Biotech, EFPIA +1 more
Panel
Tue Nov 10
09:30–09:55
From Clinical Success to Commercial Readiness: Strategic Lessons in Bringing Advanced Therapies to Patients
Lessons from preparing cell and gene therapies for launch by planning manufacturing, approval and reimbursement alongside the clinical trials.
Talk
Wed Nov 11
09:30–09:55
Bridging Therapeutic Areas: Navigating the Oncology–Autoimmune Convergence in Cellular Therapies
How cell therapies built for cancer are moving into autoimmune disease, and how trial endpoints, risk expectations and teams must change.

Explore the full BIO-Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Cologne. Leave your work email and we’ll be in touch.

Privacy

Download the full BIO-Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers in ecosystem innovation

Tell us what you sell and we’ll find the people at organizations working on ecosystem innovation most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse BIO-Europe 2026 by

Not affiliated with or endorsed by BIO-Europe or its organizers. Submit a correction